Caladrius Biosciences, Inc. (formerly NeoStem) is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s subsidiary, PCT, is a development and manufacturing partner exclusively focused on the cell therapy industry. PCT provides a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage, and distribution, as well as expert consulting and regulatory support.

Type
Public
HQ
Bernards, US
Founded
2006
Size (employees)
209 (est)
Caladrius was founded in 2006 and is headquartered in Bernards, US
Report incorrect company information

Caladrius Office Locations

Caladrius has offices in New York and Bernards
Bernards, US (HQ)
4th Floor 106 Allen Rd
New York, US
350 420 Lexington Ave
Show all (2)
Report incorrect company information

Caladrius Financials and Metrics

Caladrius Financials

Caladrius's revenue was reported to be $35.28 m in FY, 2016 which is a 56.9% increase from the previous period.
USD

Net income (Q1, 2018)

(5 m)

EBIT (Q1, 2018)

(5.2 m)

Market capitalization (23-May-2018)

38.7 m

Closing share price (23-May-2018)

4

Cash (31-Mar-2018)

21.6 m
Caladrius's current market capitalization is $38.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

14.7 m17.9 m22.5 m35.3 m

Revenue growth, %

22%25%57%

Cost of goods sold

12.9 m15.7 m20.2 m31.1 m

Gross profit

1.7 m2.3 m2.3 m4.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

3.7 m4.1 m4.5 m4.1 m3.2 m5.9 m5.9 m7.5 m8.3 m9.3 m7.9 m

Cost of goods sold

3 m3.8 m3.7 m4 m3.4 m5.8 m4.8 m6.2 m7.1 m8.6 m8 m

Gross profit

731 k230.1 k811.6 k105.4 k(196.3 k)68.2 k1.1 m1.3 m1.2 m706.3 k(119.6 k)

Gross profit Margin, %

20%6%18%3%(6%)1%18%17%15%8%(2%)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

46.1 m19.2 m20.3 m14.7 m29.2 m

Accounts Receivable

Inventories

1.3 m

Current Assets

50.8 m36.3 m29.3 m24.6 m61.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

16.9 m41.4 m32.9 m32.1 m19.1 m36.2 m24 m25.4 m17.7 m18.6 m12 m23 m21.6 m

Inventories

529.4 k1.5 m2 m2.1 m

Current Assets

20.3 m46.6 m40.9 m41.4 m29 m47.5 m38.5 m35.6 m29.3 m30 m21.9 m70.4 m54.5 m

PP&E

11.3 m13.8 m15.6 m15.7 m15.9 m16.8 m17.1 m16.9 m17 m17.1 m16.8 m432.9 k178.1 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(39.5 m)(55.5 m)(81 m)(33.3 m)22.2 m

Depreciation and Amortization

1.6 m2.2 m2.7 m2.7 m372 k

Inventories

(758.8 k)(2.8 m)

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(26.8 m)(13.8 m)(26.6 m)(43.8 m)(19.2 m)(36.4 m)(47.8 m)(12 m)(19.9 m)(27.2 m)(9.8 m)28.7 m(5 m)

Depreciation and Amortization

1.2 m444.5 k987.7 k1.6 m604.4 k1.3 m1.9 m737.2 k1.4 m2.1 m655.3 k193.8 k87.3 k

Inventories

583.7 k(205.6 k)(762.8 k)(872.1 k)

Cash From Operating Activities

(19.7 m)(11.3 m)(22.5 m)(36 m)(14.2 m)(21.8 m)(30.5 m)(8 m)(14.6 m)(20.3 m)(10.1 m)(638.1 k)
USDY, 2018

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information